Company Profile  0-9   A   B   C   D   E   F   G   H   I   J   K   L   M   N   O   P   Q   R   S   T   U   V   W   X   Y   Z 
  Search DR Directory
Symbol Lookup  

Program Information Company Profile Company Market News Interactive Charting Company Financials Company Calendar of Events DR Program News/Events Company Books Close / Open Notices Company Capital Raisings Company Certification Papers Company Corporate Actions Company Dividends / GDN Interest Payments Company DSF Notices Shareholder Information Estimated Fee Calculator

Company Profile

BioLineRX (NASDAQ: BLRX)
8:00 PM UTC, 04/17/25
Last: $2.88 Change: +0.13 %Change: +4.88% Volume: 8,953
Detailed Quote
Open: $ 2.75   Volume: 8,953
High: $ 2.88   Yield(%) 0.00
Low: $ 2.74   P/E Ratio (ttm): n/a
Dividend ($): n/a   Market Cap ($): 10.72M
EPS ($) -4.48   Shares Out: 3.72M
M = Million B = Billion
DR Program Information
Company name BioLineRX
Current Book Status
CUSIP09071M304  (Active)
Ratio (ORD:DRS) 600 :1
DR TickerBLRX
ORD TickerBLRX-IL
DR ISINUS09071M304
ORD ISINIL0011015182
SedolB1RGMP6
DR TypeADR
CountryIsrael
Active Date 7/25/2011
Inactive Date 
GICS IndustryBiotech & Pharma
Depositary BoNY (Sponsored)
Unsponsored
Depositaries 
Custodians
Flags 
Product Milestones Ratio change (old: 15 ORD: 1 ADS) CUSIP change (old: 09071M205) effective 1/30/2025.
Comments 

search other DR programs

Price Performance
% Price Change (last 4 weeks): -15.79
% Price Change (last 13 weeks): -40.94
% Price Change (last 26 weeks): -84.42
% Price Change (last 52 weeks): -88.75
% Price Change (year to date): -66.36
Management Effectiveness
Return on Equity (%): -69.11
Return on Assets (%): -17.93
Return on Invested Capital (%): -74.40
Profitability
Gross Profit Margin (%): 65.33
Net Profit Margin (%): -31.86
Operating Profit Margin (%): -67.03
Price & Volume
50-day Moving Average: $3.20
200-day Moving Average: $14.79
Avg. Daily Vol. (last 50 days): 45,225
Avg. Daily Vol. (last 200 days): 80,815
52-wk high: $35.60
52-wk low: $2.30
Bid: $2.82
Ask: $2.88
Company Information
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.
BioLineRX
Modi'in Technology Park 2 HaMa'ayan Street
Modi'in HM 7177871

Phone: 972.8.642.9100
Fax: 972.8.642.9101
http://www.biolinerx.com
Per Share Data
Earnings (1year) ($): -4.48
Annual Dividend ($): 0.00
Current P/E Ratio (ttm): n/a
Book Value ($): 6.04
Cash Flow ($): -2.30
Valuation Ratios
Price/Earnings (x): n/a
Price/Sales (x): 0.59
Price/Book (x): 1.42
Price/Cash Flow (x): n/a
Financial Strength
Quick Ratio (x): 1.56
Current Ratio (x): 1.76
LT Debt/Equity (x): 74.58
Total Debt/Equity (x): 111.73



Quotes displayed with 15 minutes delay. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. News provided by MT Newswires, a Division of MidnightTrader, Inc. Events Data provided by Wall Street Horizon. ©2021 Wall Street Horizon, Inc.